Detalhe da pesquisa
1.
Orally available and efficacious α4ß1/α4ß7 integrin inhibitors.
Bioorg Med Chem Lett
; 23(15): 4370-3, 2013 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23777782
2.
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.
Mol Cancer Ther
; 21(8): 1326-1336, 2022 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35666803
3.
RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-mediated gene silencing in mice.
Mol Pharmacol
; 79(6): 953-63, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21427169
4.
Novel Ex Vivo Zymography Approach for Assessment of Protease Activity in Tissues with Activatable Antibodies.
Pharmaceutics
; 13(9)2021 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34575469
5.
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents.
Cancer Immunol Res
; 9(12): 1451-1464, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34635485
6.
The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice.
Theranostics
; 10(13): 5815-5828, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32483421
7.
Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.
Sci Transl Med
; 5(207): 207ra144, 2013 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-24132639